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Objective: To study the surgical morbidity and outcomes of patients with markedly bulky cervical
squamous cell carcinoma ( 6 cm Cx-SCC) who underwent radical hysterectomy (RH) with and without
neoadjuvant chemotherapy (NACT).
Materials and methods: This retrospective study enrolled patients with International Federation of Gy-
necology and Obstetrics (FIGO) IB markedly bulky Cx-SCC who were treated with either three courses of
weekly single agent cisplatin NACT (50 mg/m2) and subsequent radical hysterectomy (NACT-RH) or
direct radical hysterectomy (RH) between 1996 and 2001. A total of 60 patients fulﬁlled the criteria,
including 35 and 25 patients with NsACT-RH and RH, respectively.
Results: There was no statistically signiﬁcant difference in basic characteristics between the two groups,
except the smaller pathological tumor size, less blood loss, and lower immediate complication rate in the
NACT-RH group. Median survival was 143.8 months in the NACT-RH group and 129.8 months in the RH
group, respectively, without a statistically signiﬁcant difference. Multivariate analysis showed that large
pathological tumor size [hazard ratio (HR) 10.66, 95% conﬁdence interval (CI) 2.93e38.80], the presence
of para-aortic lymph node metastases and an immediate complication (HR 8.33 and 4.55, 95% CI 1.66
e41.75 and 1.35e15.27, respectively) contributed to a worse outcome.
Conclusion: Weekly single agent cisplatin NACT indeed reduced the pathological tumor size and im-
mediate complication rate during the RH, supporting the feasibility of subsequent RH in the management
of patients with bulky Cx-SCC.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.epartment of Obstetrics and
of Medicine, Taipei Veterans
i 112, Taiwan.
ng@ym.edu.tw (P.-H. Wang),
work.
bstetrics & Gynecology. PublishedIntroduction
Cervical (Cx) cancer is still a serious health problem, second only
to breast cancer as the most common female malignancy in both
incidence andmortality worldwide [1]. In recent years, both overall
survival (OS) and disease-free survival rates have been signiﬁcantly
improved as a result of advances in the technologies of surgery,
chemotherapy (CT), and radiotherapy (RT) [2]. However, patientsby Elsevier Taiwan LLC. All rights reserved.
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the high recurrence rate and worse prognosis, compared to those
with smaller tumors at the same stage [3]. In this situation, the role
of surgery [radical hysterectomy and pelvic lymph node dissection
(RH and PLND)] is controversial [2], compared with the role of
concurrent chemoradiotherapy (CCRT). CCRT is now considered the
treatment of choice for patients who are not candidates for initial
surgical therapy [4e7]. In clinical practice, Cx cancer is classiﬁed
according to the clinical International Federation of Gynecology
and Obstetrics (FIGO) staging system [1], and this is mainly based
on clinical examination, which makes the selection of those that
will beneﬁt from surgical intervention much more difﬁcult.
Therefore, modiﬁcation of the treatment strategy, including the use
of neoadjuvant chemotherapy (NACT), RT (external beam RT or
brachytherapy) and CCRT, is much more frequent either before or
after surgery.
To perform successful surgery, the induction of tumor shrinkage
might be of most importance. This not only facilitates radical
excision but also makes reconstruction easier. Although many
strategies can be used to bring about tumor shrinkage, chemo-
therapymay be effective. NACT is well accepted in themanagement
of various types of tumor, such as breast cancer [8]. However, the
application of NACT for Cx cancer is debated, although it is often
used in Asia, Italy, and South America [2]. The theoretical rationale
for the use of NACT in Cx cancer includes the aforementioned in-
duction of tumor shrinkage to facilitate radical excision, and a
possible sterilization of lymph nodes and parametrial tissues,
thereby reducing the risk factors of adjuvant therapy after surgery
[1]. NACT regimens for Cx cancer vary, ranging from single-agent to
many forms of multiagent regimens. In addition, the therapeutic
interval also varies, ranging from every week to every 2, 3, or
4 weeks [9e15]. The clinical effects of NACT are not always
consistent with the theoretical beneﬁts, and that is why there is a
great deal of conﬂicting data in the literature [9e15]. The available
reports on the effect of NACTon Cx cancer are mainly with regard to
FIGO IB and IIA bulky tumors, sometimes up to stage IVA [9e16].
The heterogeneity of the study population, including the differ-
ences in stage and cell types, and comorbidity with other medical
or surgical illnesses make it difﬁcult to reach a conclusion [9e16]. In
addition, there is no study addressingmarkedly bulky Cx squamous
cell carcinoma (Cx-SCC) ( 6 cm). Therefore, we conducted this
retrospective study to investigate the effect of NACT on the man-
agement of early-stage bulky Cx-SCC before surgery.
Materials and methods
The population of this study was derived from the Cancer Reg-
istry in the Department of Obstetrics and Gynecology of Taipei
Veterans General Hospital. All patients withmarkedly bulky 6 cm
Cx-SCC undergoing RH and PLND between 1996 and 2001 were
evaluated. The study aimed to compare the difference between
weekly cisplatin-based NACT-RH and RH as an initial therapy for
patients with  6 cm Cx-SCC. To make this study even more uni-
form and consistent, eligibility criteria were as follows: histologi-
cally veriﬁed uterine Cx-SCC; locally advanced stage FIGO IB disease
without parametrial invasion or distant metastases; initial mag-
netic resonance image- or computed tomography-measurable tu-
mor diameterS 6 cm in size; age younger than 65 years with a life
expectancy  1 year; World Health Organization performance
status of 0-2, treatment with type III RH and pelvic and para-aortic
lymphadenectomy, no prior treatment with RT or CT, but three
courses of weekly cisplatin 50 mg/m2 were permitted; absence of
prior malignant diseases or surgical illness, but cesarean section
was permitted; and adequate renal, pulmonary, hepatic, bone
marrow, and cardiac function.Basic characteristics of the patients, including surgical param-
eters and complications, were recorded. Immediate complication
included visceral organ injury, prolonged hospitalization because of
instability or signiﬁcant delay ( 7 days) of immediate post-
operative adjuvant therapy (such as CT, RT, or CCRT); difﬁculty in
urination and constipation were excluded. Late complication
included any therapy-related sequelae, such as long-term ureter or
urethra catheter use ( 12 months), radiation colitis, and cystitis.
We used the following parameters to deﬁne the radiation colitis or
radiation cystitis. The diagnosis of radiation colitis and/or cystitis
was made when those patients who had at least one attack of anal
bleeding and gross hematuria that required medical care for relief
and the diagnosis of radiation colitis and/or cystitis had excluded
other radiation-unrelated or tumor-related possibility at ﬁrst, such
as infection, acute gastroenteritis, hemorrhoid, or tumor
recurrence.
Periodic follow-ups of patients, including postoperative adju-
vant therapy, such as CT, RT, or CCRT in accordance with the pa-
tients' risk analysis [17e22], physical examination, vaginal cytology,
and imaging or intravesical ureterography, continued until the
patients died or for more than 5 years after surgery. To determine
an appropriate decision point for the continuous data, such as age,
tumor size, blood loss, and number of lymph nodes, the receiver
operating characteristic was used [23].
Survival was determined on the basis of treatment and patient
outcomes. Estimates of the proportion of OS were calculated by the
Kaplan-Meier procedure, and differences in survival were evalu-
ated via the log-rank test. Covariance analysis and the hierarchic
Chi-square test were used to control for potential confounding
factors in the comparison of clinicopathologic characteristics and
risk factors. The log-rank test, hazard ratio (HR), and 95% conﬁ-
dence interval (CI) of mortality from cancer were calculated via the
Cox proportional hazards model with univariate and multivariate
analysis of OS. Statistical signiﬁcance was determined by an un-
paired two-tailed Student t test using a pooled estimator of vari-
ance, and was deﬁned as p < 0.05. SPSS version 20 (SPSS, Chicago,
IL, USA) was used for statistical analysis.
Results
A total of 60 patients fulﬁlled the aforementioned criteria and
were enrolled into the analysis. Thirty-ﬁve patients received three
cycles of weekly intravenous cisplatin 50 mg/m2-based NACT, fol-
lowed by RH and PLND and para-aortic lymph node sampling
(NACT-RH group) on Day 18 after the ﬁrst course of NACT. The
remaining patients (n ¼ 25) underwent RH and PLND and para-
aortic lymph node sampling (RH group). Follow-up ranged from
11 months to 205 months (median 138 months).
There was no statistically signiﬁcant difference in age, initial
image tumor size, number of removed lymph nodes, cell grade, and
presence of deep stromal invasion, vaginal invasion, parametrial
invasion, lymphovascular invasion, and pelvic or para-aortic lymph
node invasion between the two groups (Table 1). The percentage of
patients in both groups who were treated with postoperative
adjuvant therapy was also similar. The mortality rate seemed to be
lower in the NACT-RH group (37.1% in the NACT-RH group and
48.0% in the RH group), although without a statistically signiﬁcant
difference. Pathological tumor size, estimated blood loss during
operation, and immediate postoperative complications were
signiﬁcantly different between the two groups. In the NACT-RH
group, the pathological tumor size was signiﬁcantly smaller
(4.5 ± 1.4 cm vs. 5.7 ± 0.8 cm, p < 0.001). In addition, a lesser
amount of estimated blood loss during the RH procedure was also
noted in the NACT-RH group (558 ± 1328 mL vs. 930 ± 356 ml,
p < 0.001). The immediate postoperative complication rate overall
Fig. 1. Overall survival (OS) of all patients with bulky squamous cell carcinoma of the
cervix ( 6 cm) undergoing primary treatment with either three courses of weekly
cisplatin neoadjuvant therapy and radical hysterectomy (NACT-RH) or direct radical
hysterectomy (RH). The OS rate of all patients was 58.3%, that of the NACT-RH group
was 62.9%, and that of the RH group was 52%. p ¼ 0.512.
Table 1
Clinical characteristics of patients with bulky-sized squamous cell carcinoma of the
cervix.
Characteristics NACT þ RH
n ¼ 35 (%)
RH
n ¼ 25 (%)
p
Age (y) 48.9 ± 9.3 50.5 ± 7.6 0.476
Image size (cm) 6.4 ± 0.5 6.2 ± 0.5 0.234
Pathological size (cm) 4.5 ± 1.4 5.7 ± 0.8 <0.001
Estimated blood loss (mL) 558 ± 1328 930 ± 356 <0.001
Number of pelvic LN metastasis 1.6 ± 2.6 1.4 ± 2.8 0.791
Number of removed pelvic LN 23.5 ± 5.0 26.3 ± 6.6 0.072
Number of paraeaortic LN metastases 0.4 ± 1.0 0.24 ± 0.7 0.500
Number of removed paraeaortic LN 2.6 ± 1.7 3.3 ± 2.1 0.158
Cell grade
Good-to-moderate differentiation 30 (85.7%) 21 (84.0%) 0.944
Poor differentiation 5 (14.3%) 4 (16.0%)
DSI (yes) 31 (88.6%) 23 (92.0%) 0.663
LVSI (yes) 22 (62.9%) 16 (64.0%) 0.928
Vaginal invasion (yes) 5 (14.3%) 3 (12.0%) 0.797
Parametrial invasion (yes) 3 (8.6%) 2 (8.0%) 0.937
Pelvic LN metastasis (yes) 13 (37.1%) 8 (32.0%) 0.681
Paraeaortic LN metastasis (yes) 5 (14.3%) 3 (12.0%) 0.797
Adjuvant therapy (yes) 19 (54.3%) 16 (64%) 0.452
Types of adjuvant therapy
None 16 (45.7%) 9 (36.0%) 0.669
CCRT 6 (17.1%) 7 (28.0%)
CT 4 (11.4%) 4 (16.0%)
RT 9 (25.7%) 5 (20.0%)
Immediate complication (yes) 2 (5.7%) 8 (32.0%) 0.007
Late complication (yes) 7 (20.0%) 8 (32.0%) 0.290
Radiation-induced colitis 2 (5.7%) 4 (16.0%) 0.190
Radiation-induced cystitis 4 (11.4%) 4 (16.0%) 0.608
>12-mo ureter or urethra catheter use 3 (8.6%) 6 (24.0%) 0.099
Recurrence of disease (yes) 13 (37.1%) 12 (48.0%) 0.400
Recurrence site
None 22 (62.9%) 13 (52.0%) 0.846
Pelvis 1 (2.9%) 1 (4.0%)
Distant site 8 (22.9%) 8 (32.0%)
Both 4 (11.4%) 3 (12.0%)
Diseaseefree survival (mo) 99.7 ± 69.7 90.0 ± 72.1 0.602
Overall survival (mo) 107.6 ± 60.4 104.0 ± 60.2 0.821
Died of disease (yes) 13 (37.1%) 12 (48.0%) 0.400
CCRT ¼ concurrent chemoradiation; CT ¼ chemotherapy; DSI ¼ deep stromal in-
vasion; LN ¼ lymph node; LVSI ¼ lymphovascular space invasion;
NACT ¼ neoadjuvant chemotherapy; RT ¼ radiation.
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p ¼ 0.007). Almost three-ﬁfths of patients were treated with
postoperative adjuvant therapy, such as CCRT, RT, and CT.
During the follow-up, 25 patients had recurrence, and all died of
Cx cancer-related diseases. The overall survival rate was 58.3%. In
the NACT-RH group, the OS rate was 62.9%, compared with 52% in
the RH group (Fig. 1). The median survival time of the patients in
the NACT-RH and RH groups was 143 months (ranging from 23.4 to
205.7 months) and 129 months (ranging from 11.2 to
203.5 months), respectively. Although the OS rate of the NACT-RH
group seemed to be longer, it did not reach a statistically signiﬁcant
level (p ¼ 0.512). The Kaplan-Meier procedure identiﬁed the sig-
niﬁcant prognostic factors as (A) pathological tumor size ( 5.3 cm
vs. > 5.3 cm, p < 0.001), (B and C) presence of pelvic or para-aortic
lymph nodemetastases (no vs. yes, p< 0.001), (D and E) presence of
immediate or late complication (no vs. yes, p ¼ 0.002, and
p ¼ 0.020, respectively), and (F) recurrence (no vs. yes, p ¼ 0.004)
(Fig. 2). In addition, patients who had a long-term urinary difﬁculty
had a worse outcome (HR 2.93, 95% CI 1.21e-7.08).
Because the decision of postoperative adjuvant therapy was
made in accordance with the patients' risk analysis [17e22], and
most decisions were based on histopathological ﬁndings, such as a
large-sized tumor, positive invasion of the cut end, presence of
pelvic and/or para-aortic lymph nodes, and deep stromal invasion
(Table 2), all would contribute to the worse prognosis, althoughmany were not statistically signiﬁcant in multivariate analysis
(Table 3). Therefore, those patients who were treated with post-
operative adjuvant therapy might have more badly pathological
risk factors than those patients without adjuvant therapy. Table 2
conﬁrmed this ﬁnding. Among these pathological risk factors, the
presence of lymph node metastases either in the pelvis or para-
aortic area was statistically signiﬁcantly frequently found in pa-
tients who were treated with adjuvant therapy. These ﬁndings
might explain why these patients after adjuvant therapy still had a
worse outcome (Fig. 3).
Multivariate analysis showed that large pathological tumor size
(HR 10.66, 95% CI 2.93e38.80), the presence of para-aortic lymph
node metastases, and an immediate complication (HR 8.33 and
4.55, 95% CI 1.66e41.75 and 1.35e15.27, respectively) contributed
to a worse outcome (Table 3).
Discussion
In our database, 60 of 689 patients (8.7%) undergoing RH within
the study period received the diagnosis of Cx-SCC  6-cm.
Compared to those with smaller tumors at the same stage, early-
stage bulky Cx-SCC has long been recognized as high risk,
because of the high recurrence rate and worse prognosis [3]. Many
strategies have been used in an attempt to improve the prognosis
and/or survival, especially for those patients who were treated
mainly with surgery. The role of NACT in markedly bulky Cx-SCC
was evaluated in this study. In agreement with the aforemen-
tioned reports, the OS rate of all patients, whether or not NACT was
used, was 58.3%.
This rate was inferior to the OS of those patients with FIGO IB
Cx-SCC or conventionally deﬁned FIGO IB2 (a cut value of the tumor
size  4-cm Cx-SCC) who were treated with RH and PLND as the
primary treatment in our hospital, because the 5-year OS rate
ranged from 78% to 92% during different study periods
[17e19,22,24].
Compared with recent studies on NACT [7,9e16], the main dif-
ference in this study was the use of a single agentdcisplatin high-
dose density CT (50 mg/m2) dwith a very short interval before
surgery (18 days in our study), even though this dose seemed to be
Fig. 2. The following parameters are prognostic factors of the patients with bulky squamous cell carcinoma of the cervix ( 6 cm) undergoing either three courses of weekly
cisplatin neoadjuvant therapy and radical hysterectomy or direct radical hysterectomy: (A) pathological size ( 5.3 cm vs. >5.3 cm, p < 0.001); (B) presence or absence of pelvic
lymph node metastases (p < 0.001); (C) presence or absence of para-aortic lymph node metastases (p < 0.001); (D) presence or absence of immediate complication (p ¼ 0.002); (E)
presence or absence of late complication (p ¼ 0.020); and (F) occurrence of recurrence (p ¼ 0.004). LN meta ¼ lymph node metastasis; OS ¼ overall survival.
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[15]. The concept that a shorter cycle length in combination with
higher dose intensity tended to show an advantage for NACT was
supported by a recent study [15]. Mountzios et al [25] suggested
that the interval between CT should not exceed 14 days and thedose of cisplatin has to be greater than 25 mg/m2 per week. This is
important not only for surgery but also from a quality-of-life
perspective (psychological aspect) [15]. As mentioned previously,
in theory, NACT provides beneﬁts not only during surgery but also
postoperatively. NACT can reduce both tumor volume and lymph
Table 2
Clinical characteristics of patients with and without adjuvant therapy.
Characteristics No adjuvant
treatment,
n ¼ 25 (%)
Adjuvant
therapy,
n ¼ 35 (%)
p
Image size (cm) 6.2 ± 0.4 6.5 ± 0.6 0.017
Pathological size (cm) 4.7 ± 1.3 5.2 ± 1.3 0.114
Cell grade
Good-to-moderate
differentiation
23 (92.0%) 28 (80.0%) 0.199
Poor differentiation 2 (8.0%) 7 (20.0%)
DSI (yes) 24 (96.0%) 30 (85.7%) 0.190
LVSI (yes) 17 (68.0%) 21 (60.0%) 0.526
Vaginal invasion (yes) 2 (8.0%) 6 (17.1%) 0.304
Parametrial invasion (yes) 1 (4.0%) 4 (11.4%) 0.305
Pelvic LN metastasis (yes) 0 (0.0%) 21 (60.0%) <0.001
Para-aortic LN
metastasis (yes)
0 (0.0%) 8 (22.9%) 0.010
DSI ¼ deep stromal invasion; LN ¼ lymph node; LVSI ¼ lymphovascular space
invasion.
Table 3
Univariate and multivariate Cox regression analyses.
Characteristics Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Treatment
RH 1 (Ref) 1 (Ref)
NACT þ RH 0.77 (0.35e1.69) 0.514 0.83 (0.26e2.65) 0.753
Age (y)
 50 1 (Ref) 1 (Ref)
> 50 1.05 (0.48e2.31) 0.900 1.89 (0.59e6.06) 0.282
Image size (cm)
 6 1 (Ref) 1 (Ref)
> 6 1.67 (0.75e3.72) 0.212 1.83 (0.41e5.32) 0.546
Pathological size (cm)
 5.3 1 (Ref) 1 (Ref)
> 5.3 5.45 (2.32e12.77) < 0.001 10.66 (2.9e38.80) < 0.001
Blood loss (mL)
 650 1 (Ref) 1 (Ref)
> 650 1.62 (0.74e3.55) 0.231 1.61 (0.55e4.76) 0.385
Number of removed pelvic LN
 23 1 (Ref)
> 23 0.58 (0.27e1.27) 0.175
Number of removed para-aortic LN
 3 1 (Ref)
> 3 1.35 (0.61e3.00) 0.466
Cell grade
1 1 (Ref)
2 1.63 (0.22e12.11) 0.634
3 1.18 (0.12e11.33) 0.887
DSI
No 1 (Ref) 1 (Ref)
Yes 0.27 (0.10e0.73) 0.010 0.30 (0.07e1.37) 0.121
LVSI
No 1 (Ref) 1 (Ref)
Yes 1.44 (0.60e3.45) 0.414 1.07 (0.25e4.57) 0.925
Vaginal invasion
No 1 (Ref) 1 (Ref)
Yes 0.53 (0.13e2.26) 0.392 2.57 (0.34e19.77) 0.364
Parametrial invasion
No 1 (Ref) 1 (Ref)
Yes 0.39 (0.05e2.87) 0.354 0.86 (0.08e9.63) 0.903
Pelvic LN metastasis
No 1 (Ref) 1 (Ref)
Yes 4.41 (1.97e9.89) < 0.001 2.76 (0.68e11.19) 0.156
Para-aortic LN meta
No 1 (Ref) 1 (Ref)
Yes 4.99 (2.12e11.74) < 0.001 8.33 (1.66e41.75) 0.010
Adjuvant therapy
No 1 (Ref) 1 (Ref)
Yes 2.93 (1.17e7.35) 0.022 1.73 (0.28e10.87) 0.557
Types of adjuvant therapy
None 1 (Ref)
CCRT 2.79 (0.93e-8.31) 0.066
Table 3 (continued )
Characteristics Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
CT 4.81 (1.5e14.96) 0.007
RT 2.21 (0.71e6.86) 0.170
Immediate complication
No 1 (Ref) 1 (Ref)
Yes 3.74 (1.60e8.76) 0.002 4.55 (1.35e15.27) 0.014
Late complication
No 1 (Ref) 1 (Ref)
Yes 2.61 (1.17e-5.83) 0.020 1.31 (0.31e5.48) 0.713
Radiation-induced colitis
No 1 (Ref)
Yes 1.49 (0.45e4.98) 0.519
Radiation-induced cystitis
No 1 (Ref)
Yes 1.85 (0.69e4.95) 0.218
> 12-mo ureter or urethra catheter use
No 1 (Ref)
Yes 2.93 (1.21e7.08) 0.017
Recurrence
No 1 (Ref)
Yes 619.9 (7.9e48904) 0.004
Recurrent site
Nil 1 (Ref)
Pelvis 623997 (0e2.453E65) 0.849
Distant site 589728 (0e2.302E65) 0.849
Both sites 1860001 (0e7.2E65) 0.837
CCRT ¼ concurrent chemoradiation; CT ¼ chemotherapy; DSI ¼ deep stromal in-
vasion; LN ¼ lymph node; LVSI ¼ lymphovascular space invasion;
NACT ¼ neoadjuvant chemotherapy; R ¼ radiation.
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factors that indicate adjuvant RT [15]. Reduction of tumor volume
makes surgery easier (possibly less radical), especially parametrial
resection, and thus, a reduction in the number of complications
would be expected [26, 27]. In this study, NACT indeed signiﬁcantly
decreased the immediate complication rate, from 32% to 5.7%,
although it did not statistically signiﬁcantly decrease the need of
postoperative adjuvant therapy (54.3% vs. 64%, p ¼ 0.452), which
also contributed to the absence of a signiﬁcant difference in
disease-free survival and OS between the NACT-RH and RH groups,
respectively (99.7 ± 69.7 months vs. 90.0 ± 72.1 months, p ¼ 0.602;
107.6 ± 60.4 months vs. 104.0 ± 60.2 months, p ¼ 0.821, respec-
tively). The reasons may be secondary to the study population, who
were in a severe status, or the CT regimen itself [28]. For example,
the rate of lymph node metastases was higher in the study popu-
lation than in patients classiﬁed as conventional FIGO IB (32e37.1%
vs. 10e18%). In addition, although tumor shrinkage was signiﬁcant
in the NACTeRH group (from 6.4 ± 0.5 cm to 4.5 ± 1.4 cm), the size
of these tumors was still large ( 4 cm). That is why the worse
outcome could be related to the bulky tumor size ( 5.3 cm. vs. >
5.3 cm with a HR of 10.66, p < 0.001) and the presence of para-
aortic lymph node metastases (HR 8.33, p ¼ 0.010).
However, we still highlight the value of NACT in those patients
with marked bulky Cx-SCC who were scheduled to undergo RH,
because NACT indeed made surgery easier, with less blood loss
(558 ± 1328mL vs. 930 ± 356mL, p < 0.001) and a lower immediate
complication rate in this study.
All patients who experienced recurrence died of the disease,
suggesting that conventionally postoperative radiation-based
adjuvant therapy might not be affective in the management of
these patients after NACT-RH or RH treatment. Although those
patients who were treated with postoperative adjuvant therapy
signiﬁcantly had more unfavorable pathological risk factors, espe-
cially presence of pelvic and/or para-aortic lymph node metastases
(Table 2), the results of the current study were still consistent with
those of our previous studies, showing any adjuvant therapy added
little value for patients after RH or even though these patients had
Fig. 3. The role of adjuvant therapy in patients with bulky squamous cell carcinoma of
the cervix ( 6 cm) after primary treatment with either three courses of weekly
cisplatin neoadjuvant therapy and radical hysterectomy or direct radical hysterectomy.
(A) p ¼ 0.022. (B) p ¼ 0.033. OS ¼ overall survival.
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study, if they were classiﬁed as a high-risk group based on the
scoring system we proposed [1e22]. It was possible that the NACT
regimen for these bulky-sized tumors needed a further investiga-
tion, because three courses of weekly cisplatin 50 mg/m2 might not
provide an adequate or signiﬁcant tumor reduction and tumor size
was still the most strongly and signiﬁcantly risk factor for worse
outcome of patients with bulky-sized Cx-SCC. It was also possible
that conventionally postoperative radiation-based adjuvant ther-
apy (CCRT or RT) might not be a better choice for those high-risk
patients. Most of these patients (77%, 27/35) were treated with
radiation-based adjuvant therapy (CCRT and RT) in the current
study. By contrast, patients undergoing adjuvant therapy (who had
worse pathologic risk factors) and patients without adjuvant
therapy (who had less severe risk factors) had statistically similar
survival in multivariate analysis, suggesting that adjuvant therapy
might be beneﬁcial to the patients in certain population who had
worse pathologic risk factors, or chemotherapy could be considered
as a postoperative adjuvant therapy, even though the role of
chemotherapy is still uncertain for patients with Cx-SCC. Further-
more, a more active and intensive surgical approach might be
needed, although the role of surgical removal of the positive lymph
nodes for patients with Cx-SCC is still controversial. In the current
study, the mean number of retrieved para-aortic lymph nodes wasonly three, and this might be relatively inadequate. A more
extensive para-aortic lymphadenectomy to remove as many posi-
tive lymph nodes as possible might provide additional information
to schedule more effective therapies (systemic treatment),
including clinical trials, because every effort should be conducted to
minimize a subsequent distant failure. By contrast, the questiondis
more radical more effective?d[26] was raised, because patients
with a long-term ureter or urethra catheter use (more than
12 months after surgery) showed the worse prognosis. More trials
are needed to determine how to balance the risks/beneﬁts of
treatment for these patients with highly risky and bulky-sized Cx-
SCC to provide an opportunity of better survival.
There are some limitations in the current study. First, this was a
retrospective study, and selection bias inherent to the type of
design may have been introduced in this study. The best way to
avoid or minimize this bias is to conduct a prospective randomized
study, but there should be a high number of patients enrolled to
show a statistically signiﬁcant difference [2]. However, retrospec-
tive study with large datasets is still the best way to investigate this
issue. Second, the sample size of patients was small in this study.
But it is not easy to enroll an adequate number of patients with Cx
cancer, especially with markedly bulky tumors, such as in  6-cm
Cx-SCC, because Cx cancer may become a relatively rare disease
in some areas in the future, if a nationwide screening program and
the introduction of human papilloma virus vaccination in the
teenage population can be continued. Third, the diagnoses of late
complications were only made by the patients' needs for medical
care, but the severity was not graded. In addition, late complica-
tions might not be totally revealed in the limited items, such as
radiation colitis and cystitis, and long-term ureter or catheter use
(12 months). Despite these limitations, this is a relatively large
studywith a long-term follow-up to investigate the potential role of
NACT in the management of patients with Cx-SCC  6-cm.
Finally, without a randomized study comparing NACT-RH with
CCRT [15] or the signiﬁcant beneﬁts of OS with a comparison of
direct RH in this study, the choice of NACT-RH in the management
of markedly bulky Cx-SCC, especially the use of three cycles of
weekly 50 mg/m2 cisplatin, would need further conﬁrmation.
However, we still believe that NACT is a feasible experimental
treatment method, because in this study, we found a signiﬁcant
decrease in blood loss during operation, a decrease in the patho-
logical tumor size and immediate complication rate.
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